Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지

Prophylaxis of Venous Thromboembolism in Patients with Pancreatic Cancer

췌장암 환자에서 정맥 혈전증 예방

  • Lee, Kang Won (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine) ;
  • Lee, Jae Min (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine) ;
  • Lee, Hong Sik (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine)
  • 이강원 (고려대학교 의과대학 내과학교실, 고려대학교 안암병원 소화기내과) ;
  • 이재민 (고려대학교 의과대학 내과학교실, 고려대학교 안암병원 소화기내과) ;
  • 이홍식 (고려대학교 의과대학 내과학교실, 고려대학교 안암병원 소화기내과)
  • Received : 2020.05.26
  • Accepted : 2020.06.16
  • Published : 2020.06.30

⟨ Previous Next ⟩

Abstract

Prognosis of patients with pancreatic cancer is poor due to difficulty in early diagnosis and low resectability rate at the time of diagnosis. Apart from the progression of cancer, venous thromboembolism - a complication that can increase patient mortality - is known to occur frequently in pancreatic cancer. This review was aimed at identifying whether venous thromboembolism is more common in pancreatic cancer than in other cancer types. In addition, we reviewed several studies to determine whether thromboprophylaxis increases the survival rates of patients with pancreatic cancer.

Keywords

Acknowledgement

This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2018R1C1B6006044).

References

  1. 보건복지부, 중앙암등록본부, 국립암센터. 국가암등록사업 연례 보고서(2016년 암등록통계). 2019.
  2. Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. The Lancet Oncology 2004;5(11):655-663. https://doi.org/10.1016/S1470-2045(04)01606-7
  3. Menapace LA, Peterson DR, Berry A, et al. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost 2011;106(08):371-378. https://doi.org/10.1160/TH10-12-0789
  4. Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie 2012;32(02):115-125. https://doi.org/10.5482/ha-1170
  5. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160(6):809-815. https://doi.org/10.1001/archinte.160.6.809
  6. Ansari D, Ansari D, Andersson R, et al. Pancreatic cancer and thromboembolic disease, 150 years after Trousseau. Hepatobiliary Surg Nutr 2015;4(5):325.
  7. Blom J, Osanto S, Rosendaal F. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur J Cancer 2006;42(3):410-414. https://doi.org/10.1016/j.ejca.2005.09.013
  8. Iodice S, Gandini S, Lohr M, et al. Venous thromboembolic events and organ-specific occult cancers: A review and meta-analysis. J Thromb Haemost 2008;6(5):781-788. https://doi.org/10.1111/j.1538-7836.2008.02928.x
  9. Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: A systematic review and metaanalysis. PLoS Med 2012;9(7).
  10. Oh SY, Kim JH, Lee K-W, et al. Venous thromboembolism in patients with pancreatic adenocarcinoma: lower incidence in Asian ethnicity. Thromb Res 2008;122(4):485-490. https://doi.org/10.1016/j.thromres.2007.12.015
  11. Khorana A, Culakova E, Lyman G, et al. Incidence of thromboembolic events in a prospective nationwide registry of cancer patients initiating systemic chemotherapy. J Clin Oncol 2004;22(14 Suppl):8019. https://doi.org/10.1200/jco.2004.22.90140.8019
  12. Jang M, BANG SM, Oh D. Incidence of venous thromboembolism in Korea: from the health insurance review and assessment Service database. J Thromb Haemost 2011;9(1):85-91. https://doi.org/10.1111/j.1538-7836.2010.04108.x
  13. Choi F. Venous thromboembolism in the Chinese population - experience in a regional hospital in Hong Kong. Hong Kong Med J 2002;8(6):400-405.
  14. Cheuk B, Cheung G, Cheng S. Epidemiology of venous thromboembolism in a Chinese population. Br J Surg 2004;91(4):424-428. https://doi.org/10.1002/bjs.4454
  15. Molina JAD, Gabriel ZJ, Heng BH, et al. Venous thromboembolism at the National Healthcare group, Singapore. Ann Acad Med Singapore 2009;38(6):470.
  16. Lee J-C, Ro YS, Cho J, et al. Characteristics of venous thromboembolism in pancreatic adenocarcinoma in east Asian ethnics: a large population-based observational study. Medicine 2016;95(17).
  17. Frere C, Bournet B, Gourgou S, et al. Incidence of venous thromboembolism in patients with newly diagnosed pancreatic cancer and factors associated with outcomes. Gastroenterology 2019.
  18. Sgouros J, Maraveyas A. Excess premature (3-month) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events. A hypothesis based on a systematic review of phase III chemotherapy studies in advanced pancreatic cancer. Acta Oncologica 2008;47(3):337-346. https://doi.org/10.1080/02841860701687267
  19. Engelberg H. Actions of heparin that may affect the malignant process. Cancer 1999;85(2):257-272. https://doi.org/10.1002/(SICI)1097-0142(19990115)85:2<257::AID-CNCR1>3.0.CO;2-2
  20. Varki NM, Varki A, editors. Heparin inhibition of selectinmediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost 2002.
  21. Icli F, Akbulut H, Utkan G, et al. Low molecular weight heparin(LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol 2007;95(6):507-512. https://doi.org/10.1002/jso.20728
  22. van Doormaal FF, Di Nisio M, Otten H-M, et al. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011;29(15):2071-2076. https://doi.org/10.1200/JCO.2010.31.9293
  23. Pelzer U, Opitz B, Deutschinoff G, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol 2015;33(18):2028-2034. https://doi.org/10.1200/JCO.2014.55.1481
  24. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729-1735. https://doi.org/10.1001/archinte.162.15.1729
  25. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349(2):146-153. https://doi.org/10.1056/NEJMoa025313
  26. Lee AY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015;314(7):677-686. https://doi.org/10.1001/jama.2015.9243
  27. Martinez C, Katholing A, Wallenhorst C, et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. Thromb Haemost 2016;115(01):31-39. https://doi.org/10.1160/TH15-04-0350
  28. Nielsen PB, Skjoth F, Sogaard M, et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2017;356:j510.
  29. Khorana AA, Vadhan-Raj S, Kuderer NM, et al. Rivaroxaban for preventing venous thromboembolism in high-risk ambulatory patients with cancer: Rationale and design of the CASSINI trial. Thromb Haemost 2017;117(11):2135-2145. https://doi.org/10.1160/TH17-03-0171
  30. Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019;380(8):720-728. https://doi.org/10.1056/NEJMoa1814630